Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoOn – Neoadjuvant Ontruzant (SB3) in HER2-positive early breast cancer
2020-001943-21Phase 4Completed
- Sponsor
- Institut für Frauengesundheit
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Institut für Frauengesundheit. Primary endpoint: Pathological complete response (pCR) rate (ypT0; ypN0). Started Dec 2020; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-001943-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001943-21.